Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Personalis Sequencing and Interpretation Services; RTG's Genome Analytics Platform

Premium

Personalis has launched services for genomic sequencing and interpretation, including its ACE Exome and ACE Genome sequencing services, which supplement standard exome and whole-genome sequencing with additional targeted sequencing to improve accuracy and coverage of medically interpretable regions.

The company also offers standard exome and whole-genome sequencing using Illumina's TruSeq enrichment chemistry and sequencing on the HiSeq 2000 or HiSeq 2500.


Real Time Genomics has launched a genome analytics platform for use in the study of early childhood disease.

The company said that it used the Illumina Platinum Genomes dataset, a three-generation pedigree of 17 individuals sequenced at high coverage, "to demonstrate and validate the platform's ability to accurately identify disease-causing variants leveraging data from multiple genomes in a family."

RTG said the platform is compatible with data from Illumina, Life Technologies' Ion Torrent, Roche 454, and Pacific Biosciences sequencers.

The platform uses a Bayesian algorithmic framework to analyze genomic data from related individuals. It produces a report that includes single nucleotide and multiple nucleotide variants, small insertions and deletions, and structural variants.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more